TAXUS Liberté Attenuates the Risk of Restenosis in Patients With Medically Treated Diabetes Mellitus. Results From the TAXUS ATLAS Program

JACC: Cardiovascular Interventions

Volumn 2, Issue 3, 2009, Pages 240-252

  Mahmud, Ehtisham ^a   Ormiston, John A ^b   Turco, Mark A ^c   Popma, Jeffrey J ^d   Weissman, Neil J ^e   O'Shaughnessy, Charles D ^f   Mann, Tift ^g   Hall, Jack J ^h   McGarry, Thomas F ⁱ   Cannon, Louis A ^j   Webster, Mark W I ^k   Mandinov, Lazar ^l   Baim, Donald S ^l  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Mercy Hospital   (New Zealand)

^c WASHINGTON ADVENTIST HOSPITAL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e WASHINGTON HOSPITAL CENTER   (United States)

^f North Ohio Research Ltd   (United States)

^g WAKEMED HEALTH AND HOSPITALS   (United States)

^h ST VINCENT HOSPITAL   (United States)

ⁱ Oklahoma Heart Hospital   (United States)

^j Northern Michigan Hospital   (United States)

^k AUCKLAND CITY HOSPITAL   (New Zealand)

^l BOSTON SCIENTIFIC CORPORATION   (United States)

more..

Author keywords

coronary artery disease; diabetes; drug eluting stent; paclitaxel

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PACLITAXEL; TICLOPIDINE; ANTINEOPLASTIC AGENT;

ADULT; ANGIOCARDIOGRAPHY; ARTERY INTIMA PROLIFERATION; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; IN-STENT RESTENOSIS; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; THROMBOSIS; CASE CONTROL STUDY; CORONARY RESTENOSIS; ECHOGRAPHY; ENDOSCOPIC ECHOGRAPHY; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK ASSESSMENT; RISK FACTOR;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CASE-CONTROL STUDIES; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; DIABETES MELLITUS; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PACLITAXEL; RISK ASSESSMENT; RISK FACTORS; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 62149124362     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2008.12.009     Document Type: Article

References (38)

1. Kannel W.B., and McGee D.L. Diabetes and cardiovascular disease. The Framingham study. JAMA 241 (1979) 2035-2038
2. Feskens E.J., and Kromhout D. Glucose tolerance and the risk of cardiovascular disease: the Zutphen Study. J Clin Epidemiol 45 (1992) 1327-1334
3. Kip K.E., Faxon D.P., Detre K.M., Yeh W., Kelsey S.F., and Currier J.W. Coronary angioplasty in diabetic patients: The National Heart, Lung, and Blood Institute percutaneous transluminal coronary angioplasty registry. Circulation 94 (1996) 1818-1825
4. Mathew V., Gersh B.J., Williams B.A., et al. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 109 (2004) 476-480
5. Mahmud E., Bromberg-Marin G., Palakodeti V., Ang L., Creanga D., and DeMaria A. Clinical efficacy of drug eluting stents in diabetic patients: a meta-analysis. J Am Coll Cardiol 51 (2008) 2385-2395
6. Abizaid A., Kornowski R., Mintz G.S., et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 32 (1998) 584-589
7. Carrozza Jr. J.P., Kuntz R.E., Fishman R.F., and Baim D.S. Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. Ann Intern Med 118 (1993) 344-349
8. Chen C., Fang C.C., Chen Y., Yu C.L., and Wang S.P. Comparative study of angiographic outcomes following coronary stenting between diabetic and non-diabetic patients. Acta Cardiologica Sinica 18 (2002) 119-124
9. Elezi S., Kastrati A., Pache J., et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 32 (1998) 1866-1873
10. Daemen J., Garcia-Garcia H.M., Kukreja N., et al. The long-term value of sirolimus- and paclitaxel-eluting stents over bare metal stents in patients with diabetes mellitus. Eur Heart J 28 (2007) 26-32
11. Hermiller J.B., Raizner A., Cannon L., et al. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol 45 (2005) 1172-1179
12. Stone G.W., Ellis S.G., Cox D.A., et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350 (2004) 221-231
13. Dawkins K.D., Stone G.W., Colombo A., et al. Integrated analysis of medically treated diabetic patients in the TAXUS program: benefits across stent platforms, paclitaxel release formulations, and diabetic treatments. Euro Intervention 2 (2006) 61-68
14. Spaulding C., Daemen J., Boersma E., Cutlip D.E., and Serruys P.W. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 989-997
15. Kirtane A.J., Ellis S.G., Dawkins K., et al. Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials. J Am Coll Cardiol 51 (2008) 708-715
16. Patterson C., Mapera S., Li H.H., et al. Comparative effects of paclitaxel and rapamycin on smooth muscle migration and survival: role of AKT-dependent signaling. Arterioscler Thromb Vasc Biol 26 (2006) 1473-1480
17. Turco M.A., Ormiston J.A., Popma J.J., et al. Polymer-based, paclitaxel-eluting TAXUS liberte stent in de novo lesions: the pivotal TAXUS ATLAS trial. J Am Coll Cardiol 49 (2007) 1676-1683
18. Ormiston J.A., Mahmud E., Turco M.A., et al. Direct stenting with the TAXUS Liberte drug-eluting stent: results from the TAXUS ATLAS DIRECT STENT study. J Am Coll Cardiol Intv 1 (2008) 150-160
19. Turco M.A., Ormiston J.A., Popma J.J., et al. Reduced risk of restenosis in small vessels and reduced risk of myocardial infarction in long lesions with the new thin-strut TAXUS Liberté stent: one-year results from the TAXUS ATLAS program. J Am Coll Cardiol Intv 1 (2008) 699-709
20. ClinicalTrials.gov: A service of the U.S. National Institutes of Health. www.clinicaltrials.gov Accessed February 22, 2008
21. Ellis S.G., Vandormael M.G., Cowley M.J., et al., Multivessel Angioplasty Prognosis Study Group. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Circulation 82 (1990) 1193-1202
22. van der Zwet P.M., and Reiber J.H. A new approach for the quantification of complex lesion morphology: the gradient field transform; basic principles and validation results. J Am Coll Cardiol 24 (1994) 216-224
23. Mehran R., Dangas G., Abizaid A.S., et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 100 (1999) 1872-1878
24. Weissman N.J., Koglin J., Cox D.A., et al. Polymer-based paclitaxel-eluting stents reduce in-stent neointimal tissue proliferation: a serial volumetric intravascular ultrasound analysis from the TAXUS-IV trial. J Am Coll Cardiol 45 (2005) 1201-1205
25. Cutlip D.E., Windecker S., Mehran R., et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007) 2344-2351
26. D'Agostino Jr. R.B. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17 (1998) 2265-2281
27. Rosenbaum P.R., and Rubin D.B. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 79 (1984) 516-524
28. Rubin D.B. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127 (1997) 757-763
29. Winkelmayer W.C., Glynn R.J., Mittleman M.A., Levin R., Pliskin J.S., and Avorn J. Comparing mortality of elderly patients on hemodialysis versus peritoneal dialysis: a propensity score approach. J Am Soc Nephrol 13 (2002) 2353-2362
30. Schramm T.K., Gislason G.H., Kober L., et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation 117 (2008) 1945-1954
31. Axel D.I., Kunert W., Goggelmann C., et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 96 (1997) 636-645
32. Blagosklonny M.V., Darzynkiewicz Z., Halicka H.D., et al. Paclitaxel induces primary and postmitotic G1 arrest in human arterial smooth muscle cells. Cell Cycle 3 (2004) 1050-1056
33. Blagosklonny M.V., Demidenko Z.N., Giovino M., et al. Cytostatic activity of paclitaxel in coronary artery smooth muscle cells is mediated through transient mitotic arrest followed by permanent post-mitotic arrest: comparison with cancer cells. Cell Cycle 5 (2006) 1574-1579
34. Okano J., and Rustgi A.K. Paclitaxel induces prolonged activation of the Ras/MEK/ERK pathway independently of activating the programmed cell death machinery. J Biol Chem 276 (2001) 19555-19564
35. Le X.F., Hittelman W.N., Liu J., et al. Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple signaling pathways in mitosis. Oncogene 22 (2003) 484-497
36. MacKeigan J.P., Taxman D.J., Hunter D., Earp III H.S., Graves L.M., and Ting J.P. Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition. Clin Cancer Res 8 (2002) 2091-2099
37. Mitsuuchi Y., Johnson S.W., Selvakumaran M., Williams S.J., Hamilton T.C., and Testa J.R. The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel. Cancer Res 60 (2000) 5390-5394
38. Kimura M., Mintz G.S., Weissman N.J., et al. Meta-analysis of the effects of paclitaxel-eluting stents versus bare metal stents on volumetric intravascular ultrasound in patients with versus without diabetes mellitus. Am J Cardiol 101 (2008) 1263-1268